Diabetic Macular Edema

Ranibizumab biosimilar noninferior to Lucentis for DME

The ranibizumab biosimilar (Vicentis) was noninferior to ranibizumab (Lucentis) for visual acuity (VA) and central subfield thickness (CSFT) in patients with diabetic macular edema, according to a poster presented at AAO 2021. In a noninferiority double-blind clinical trial, 154 eyes of 154 patients with diabetic macular edema were randomized to...